Editors commentary

The actress Ellen Terry (1847–1928) attributed her success to the three I’s, ‘Industry, intelligence and imagination’. This is a tricolon—a useful rhetorical device that brings together ideas with a rhythm and places emphasis on the last element. What might be

Association between ASPECTS region of infarction and clinical outcome in non-acute large vessel occlusion ischaemic stroke after endovascular recanalisation

Purpose This study retrospectively investigated whether infarction in specific Alberta Stroke Program Early CT Score (ASPECTS) regions is associated with clinical outcome in patients with symptomatic non-acute internal carotid or middle cerebral artery occlusion who underwent endovascular recanalisation (ER). Methods

C5 complement inhibition and FcRn modulation in generalized myasthenia gravis. Fast-acting but short-lived therapies the use of which should prompt assertive escalation of conventional treatments

The paper by Huntemann et al1 exploits almost identical indications for the treatment of generalised myasthenia gravis (MG) with efgartigimod (a neonatal Fc receptor blocker (FcRn blocker)) and ravulizumab (a C5 complement inhibitor) to conduct an elegant real-world study comparing

Editors’ commentary

There is tension in neurology between sub-specialism and generalism, something discussed in this issue through a geographically based metaphor. Bas Bloem and colleagues make the specialist’s case that complexity within neurology’s subspecialties leads to islands of expertise, and the need

Editors commentary

Even experienced neurologists must sometimes step back from a difficult clinical problem, take out the surgical sieve from their metaphorical cupboard, and check they are not missing something. The sieve provides a reminder that alongside the more common explanations we

Consciousness

Interest in the neurobiological substrates of consciousness has risen dramatically over the last few decades. This is reflected both in the steady increase in the number of papers published and in the recent surge of adversarial collaborations, in which researchers

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Natalizumab treatment in relapsing-remitting multiple sclerosis: can we safely personalise treatment intervals? In JNNP, Toorop and coworkers present the results of the NEXT-MS trial, a clinical trial on individualised extended interval dosing (EID) of natalizumab (NTZ) in people with relapsing-remitting

WhatsApp'tan Bize Yazın